We herein have demonstrated that cHL is likely the first hematological malignancy to exhibit an aberrant expression of CK2 subunits, with CK2α being overexpressed and CK2β downregulated in HRS cells, both in HL cell lines and primary lymph nodes from cHL patients. This evidence concerns the gene CSNK2B and Hodgkins lymphoma.